New combo therapy shows promise for aggressive brain cancer
NCT ID NCT03532295
First seen Nov 21, 2025 · Last updated Jun 14, 2026 · Updated 35 times
Summary
This study tested a combination of two drugs (retifanlimab and epacadostat) plus radiation and another drug (bevacizumab) in 51 people with recurrent glioblastoma, a fast-growing brain tumor. The goal was to see if this mix could boost the immune system to fight the tumor and improve survival. The study measured how many patients were alive at 9 and 12 months after starting treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Phoenix, Arizona, 85259, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, 27157, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.